ALG1001 (Risuteganib)

Biorbyt

ALG1001 (Risuteganib)

10

Research Use Only

>98%

C22H39N9O11S

637.666

ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (alphavbeta3, alphavbeta5, and alpha5beta1) associated with angiogenesis; ALG1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, connecting the posterior aspect of the vitreous with the internal limiting membrane of the retina. In blocking this pathway, ALG-1001 helps to achieve vitreous breakdown and separation from the retina.

S(C[C@@H](C(N[C@@H]([C@@H](C)O)C(N1CCC[C@H]1C(=O)O)=O)=O)NC(CNC([C@H](CCC/N=C(\N)/N)NC(CN)=O)=O)=O)(=O)(=O)O

12352200